Metastatic colorectal cancer: Is there one standard approach? Journal Article
| Author: | Saltz, L. B. |
| Article Title: | Metastatic colorectal cancer: Is there one standard approach? |
| Abstract: | Despite enormous advances in the treatment of colorectal cancer, there is no single standard treatment approach for all patients. However, there are general principles of management that can be used to guide therapy. The clinician who fails to individualize therapy for colorectal cancer is likely not taking full advantage of all therapeutic options available. Reviewing key clinical evidence that can help inform decision-making, this article addresses important questions in colorectal cancer management, including: Should bevacizumab (Avastin) be a component of most patients' first-line treatment? Is there a role for continuing bevacizumab in subsequent regimens? Is there a role for cetuximab (Erbitux) in standard first-line chemotherapy? Are there practices in colorectal cancer that have become widely accepted without direct supportive data? |
| Keywords: | immunohistochemistry; vasculotropin; cancer survival; protein expression; treatment response; treatment failure; clinical trial; review; bevacizumab; fluorouracil; placebo; drug efficacy; drug safety; hypertension; monotherapy; antineoplastic agents; drug approval; drug megadose; neurotoxicity; antineoplastic agent; clinical practice; colorectal cancer; metabolism; metastasis; controlled clinical trial; breast cancer; neuropathy; randomized controlled trial; antineoplastic combined chemotherapy protocols; peripheral neuropathy; epidermal growth factor receptor; tumor markers, biological; camptothecin; combination chemotherapy; receptor, epidermal growth factor; antineoplastic activity; food and drug administration; drug effect; pathology; cetuximab; tumor marker; irinotecan; monoclonal antibody; rash; colorectal neoplasms; standard; gastrointestinal toxicity; antibodies, monoclonal; drug mechanism; cyclooxygenase 2 inhibitor; heart infarction; stroke; colorectal tumor; folinic acid; drug derivative; platinum complex; drug half life; tumor growth; trastuzumab; oxaliplatin; alopecia; digestive system perforation; organoplatinum compounds; leucovorin; drug binding; artery thrombosis; clinical trials; folfox protocol |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 19 |
| Issue: | 9 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2005-08-01 |
| Start Page: | 1147 |
| End Page: | 1154 |
| Language: | English |
| PUBMED: | 16255132 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 17" - "Export Date: 24 October 2012" - "CODEN: OCLGE" - "Source: Scopus" |
